Saridon was banned in India in September 2018 as part of a massive government crackdown on fixed-dose combination (FDC) drugs that lacked sufficient therapeutic justification. The ban targeted 328 FDC products, and Saridon’s specific combination of paracetamol, propyphenazone, and caffeine was flagged as potentially risky to human health. The ban was later stayed by India’s Supreme Court, allowing Saridon to return to pharmacy shelves, but the controversy highlighted real safety concerns about one of its key ingredients.
What Saridon Contains and Why It Raised Concerns
Each Saridon tablet contains three active ingredients: 250 mg of paracetamol (a common pain reliever), 150 mg of propyphenazone (a less common anti-inflammatory), and 50 mg of caffeine. Paracetamol and caffeine are widely used and well understood. The problem centers on propyphenazone.
Propyphenazone is structurally related to a older drug called aminophenazone, which has been associated with severe blood dyscrasias. That term refers to dangerous disruptions in blood cell production, including conditions where the body stops making enough white blood cells to fight infection. This connection to serious blood disorders is the core medical reason propyphenazone drew regulatory scrutiny. While propyphenazone is not identical to aminophenazone, its chemical similarity was enough to concern Indian health authorities reviewing the safety profile of FDC drugs containing it.
India’s Crackdown on Fixed-Dose Combinations
Saridon’s ban wasn’t an isolated decision targeting one product. It was part of a sweeping regulatory effort to clean up India’s pharmaceutical market, which had become crowded with combination drugs that were never properly evaluated for safety or effectiveness. The World Health Organization has approved roughly 350 FDC formulations globally, yet more than 6,000 combinations are available worldwide, many of them marketed without rigorous evidence that combining those particular ingredients offers a real benefit over taking them separately.
India’s drug market was especially affected. An expert panel set up by the Drugs Technical Advisory Board (DTAB) reviewed hundreds of FDCs and concluded that 328 of them had no therapeutic justification for their specific ingredient combinations. The panel also determined that these products could pose risks to humans. On September 7, 2018, the health ministry issued a notification banning the manufacture, sale, and distribution of all 328 FDCs under the Drugs and Cosmetics Act of 1940. Saridon’s combination of paracetamol, propyphenazone, and caffeine appeared on that list as item number 113.
The reasoning was straightforward: if there’s no proven benefit to combining these three ingredients in a single tablet, and one of those ingredients carries a risk of serious side effects, why should it remain on the market? Paracetamol alone, or paracetamol with caffeine, could address the same symptoms without the added risk from propyphenazone.
How the Supreme Court Reversed the Ban
The ban triggered an immediate response from pharmaceutical companies. Several drug makers and pharma associations filed legal challenges, and the case reached India’s Supreme Court quickly. On September 17, 2018, just ten days after the ban took effect, a bench of Justices R.F. Nariman and Indu Malhotra allowed the sale of Saridon and three other banned FDCs to resume. The court issued notice to the central government and asked for a formal reply to the manufacturers’ arguments.
The court did not grant the same relief to the remaining banned FDCs. Most of the 328 products stayed off the market. Saridon’s manufacturer successfully argued that their product deserved a different outcome, and the stay allowed it to return to pharmacies across India while the legal process continued.
This outcome left Saridon in an unusual position: technically challenged by the government’s own expert panel as lacking therapeutic justification, yet legally permitted for sale by court order. For consumers, the practical result was that Saridon remained available in India, though the safety questions about propyphenazone were never fully resolved through the legal process.
The Safety Issue With Propyphenazone
Propyphenazone works as a pain reliever and fever reducer, similar to paracetamol but through a different mechanism. The drug has been used in various countries for decades, primarily in combination products. Reported side effects at a standard 300 mg dose include tiredness, dizziness, and feelings of warmth or relaxation. These are relatively mild, but the deeper concern is the association with blood dyscrasias, which are rare but potentially life-threatening.
Several countries have restricted or removed propyphenazone-containing products from their markets over the years, driven by the same safety logic India’s regulators applied: when safer alternatives exist for treating headaches and general pain, the added risk from propyphenazone is hard to justify. Paracetamol and ibuprofen, both widely available and extensively studied, can treat the same conditions without the blood disorder risk.
What This Means for Consumers
If you’ve used Saridon for headaches or body pain, the product itself is not uniquely dangerous in a way that should cause alarm about past use. The ban was driven by a regulatory principle: combination drugs should only exist when the combination offers a clear advantage, and the ingredients should each have an acceptable safety profile. Propyphenazone didn’t meet that bar in the eyes of Indian regulators, even though the Supreme Court allowed the product to continue being sold.
For routine pain relief, single-ingredient options like paracetamol or ibuprofen carry better-established safety records and achieve the same result for most people. The caffeine in Saridon does slightly enhance pain relief, which is why paracetamol-caffeine combinations remain common and generally accepted. It’s the propyphenazone component that remains controversial, and the reason Saridon’s name appeared on a government ban list in the first place.